Regeneron 4th-qtr sales and earnings beat expectations

6 February 2020

Shares of US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) were up 2.64% at $382.00 in early trading, after it reported financial results that beat expectations.

For the fourth quarter of 2019, sales rose 13% to $2.17 billion, exceeded analysts’ forecasts of $2.10, while adjusted earnings per share (EPS) came in at $7.50, well beating expectations of $6.03.

For the full year, total revenues increased 17% to $7.863 billion. Non-generally accepted accounting principles (GAAP) net income was up 8% at $2.827 billion, or $24.67 per diluted share, for the full year 2019, compared to non-GAAP net income of $2.622 billion, or $22.84 per diluted share, for the full year 2018.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK